Corticosteroid Treatment for Metastatic Spinal Cord Compression: A Review.

Abstract

STUDY DESIGN:

Narrative review.

OBJECTIVE:

Metastatic spinal cord compression (MSCC) is a very frequent complication among cancer patients. Presenting commonly as nocturnal back pain, MSCC typically progresses to lower extremity paresis, loss of ambulatory capabilities, and paraplegia. In addition to standard treatment modalities, corticosteroid administration has been utilized in preclinical and clinical settings as adjunctive therapy to reduce local spinal cord edema and improve clinical symptoms. This article serves as a review of existing literature regarding corticosteroid management of MSCC and seeks to provide potential avenues of research on the topic.

METHODS:

A literature search was performed using PubMed in order to consolidate existing information regarding dexamethasone treatment of MSCC. Of all search results, 7 articles are reviewed, establishing the current understanding of metastatic spine disease and dexamethasone treatment in both animal models and in clinical trials.

RESULTS:

Treatment with high-dose corticosteroids is associated with an increased rate of potentially serious systemic side effects. For this reason, definitive guidelines for the use of dexamethasone in the management of MSCC are unavailable.

CONCLUSIONS:

It is still unclear what role dexamethasone plays in the treatment of MSCC. It is evident that new, more localizable therapies may provide more acceptable treatment strategies using corticosteroids. Looking forward, the potential for more targeted, localized application of the steroid through the use of nanotechnology would decrease the incidence of adverse effects while maintaining the drug's efficacy.

• Authors: Gordon D Skeoch, Matthew K Tobin, Sajeel Khan, Andreas A Linninger, Ankit I Mehta
• Journal: Global spine journal (Global Spine J) Vol. 7 Issue 3 Pg. 272-279 (May 2017) ISSN: 2192-5682 [Print] England
• PMID: 28660111 (Publication Type: Journal Article, Review)